|
Real-time Estimate
Cboe BZX
09:54:49 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 120.16 USD | -2.97% |
|
+8.53% | +83.51% |
Company Valuation: Monopar Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 40.42 | 30.62 | 5.058 | 134.2 | 436.4 | 831.2 | - | - |
| Change | - | -24.23% | -83.48% | 2,552.79% | 225.25% | 90.49% | - | - |
| Enterprise Value (EV) 1 | 40.42 | 30.62 | 5.058 | 134.2 | 296 | 712.5 | 686.7 | 663.1 |
| Change | - | -24.23% | -83.48% | 2,552.79% | 120.6% | 140.72% | -3.62% | -3.43% |
| P/E | -4.4x | -2.86x | -0.56x | -5.35x | -35.3x | -49.6x | -49.4x | -41.3x |
| PBR | - | - | - | - | 3.17x | 7.85x | 9.28x | 8.81x |
| PEG | - | -0.2x | 0x | -0.2x | 0.6x | -1.4x | -142.73x | -2.1x |
| Capitalization / Revenue | - | - | - | - | - | - | 29.4x | 9.81x |
| EV / Revenue | - | - | - | - | - | - | 24.3x | 7.83x |
| EV / EBITDA | - | - | - | - | -17.7x | -17.5x | -27.7x | -246x |
| EV / EBIT | -4.43x | -2.91x | -0.57x | -8.3x | -17.7x | -26.1x | -16.4x | -23.4x |
| EV / FCF | - | - | - | -20.9x | -24.3x | -28.4x | -34x | -86.9x |
| FCF Yield | - | - | - | -4.77% | -4.12% | -3.52% | -2.94% | -1.15% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.65 | -4.15 | -3.05 | -4.11 | -1.85 | -2.496 | -2.505 | -2.996 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 28.26 | 84.73 |
| EBITDA 1 | - | - | - | - | -16.7 | -40.77 | -24.81 | -2.694 |
| EBIT 1 | -9.127 | -10.54 | -8.831 | -16.16 | -16.7 | -27.29 | -41.79 | -28.39 |
| Net income 1 | -9.103 | -10.52 | -8.402 | -15.6 | -13.72 | -21.46 | -26.62 | -29.6 |
| Net Debt 1 | - | - | - | - | -140.4 | -118.8 | -144.6 | -168.1 |
| Reference price 2 | 16.05 | 11.85 | 1.70 | 22.00 | 65.30 | 123.84 | 123.84 | 123.84 |
| Nbr of stocks (in thousands) | 2,518 | 2,584 | 2,973 | 6,098 | 6,683 | 6,712 | - | - |
| Announcement Date | 3/24/22 | 3/23/23 | 3/28/24 | 3/31/25 | 3/27/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -49.61x | - | -17.48x | - | 831M | |
| 34.01x | 6.07x | 18.05x | 0.94% | 50.5B | |
| -22.28x | 305.61x | -22.68x | -.--% | 46.01B | |
| 49.37x | 5.74x | 31.39x | -.--% | 42.85B | |
| 32.1x | 3.15x | 13.59x | -.--% | 41.03B | |
| 29.53x | 8.51x | 21.44x | 0.39% | 32.02B | |
| 34.59x | 5.67x | 25.77x | -.--% | 16.98B | |
| 23.56x | 2.06x | 8.91x | 1.14% | 14.3B | |
| 77.58x | 4.08x | 15.82x | -.--% | 13.84B | |
| Average | 23.21x | 42.61x | 10.54x | 0.31% | 28.71B | |
| Weighted average by Cap. | 27.20x | 59.01x | 12.49x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MNPR Stock
- Valuation Monopar Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
